SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board: 
Last Post: 2/22/2017 5:06:40 PM - Followers: 832 - Board type: Free - Posts Today: 127

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: [email protected]

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Current Report Filing (8-k) 02/09/2017 04:46:25 PM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 02/09/2017 04:35:32 PM
ELTP News: Quarterly Report (10-q) 02/09/2017 04:34:39 PM
ELTP News: Current Report Filing (8-k) 12/22/2016 05:25:52 PM
ELTP News: Confidential Treatment Order (ct Order) 12/22/2016 05:17:13 PM
PostSubject
#239843  Sticky Note Maz, this has nothing to do with SequestOx WeeZuhl 01/20/17 08:56:19 PM
#239443  Sticky Note Yes IMO first SequestOx FDA Commercial approval in lasers 01/17/17 11:02:44 PM
#236265  Sticky Note Elite Pharma: The company of firsts: namtae 12/14/16 12:32:00 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#243746   Lol owc yea u picked the wrong one....I. starkd748 02/22/17 05:12:14 PM
#243745   a win win partnership that exists only on dr_lowenstein 02/22/17 05:06:40 PM
#243744   Gee and yet the PPS was .068 when Couch 02/22/17 05:02:17 PM
#243740   Yea and Nasrat has been 100% WRONG only namtae 02/22/17 04:34:03 PM
#243739   PuraCap will make $millions in Partnering with $ELTP. lasers 02/22/17 04:16:00 PM
#243738   There's nothing Elite can do to make things namtae 02/22/17 04:10:14 PM
#243737   Why are we settling with PuraCap as a aELmTPa 02/22/17 04:09:31 PM
#243736   Indeed - Puracap doesn't hand over $2.5 million Couch 02/22/17 04:06:15 PM
#243735   Elite needs to close green !!!!!!!!!! IB_ 02/22/17 03:59:24 PM
#243734   Agree mrwrm... I believe it will all hinge Gman24 02/22/17 03:56:09 PM
#243733   "spectacular" LOL , no, notta, zero evidence that dr_lowenstein 02/22/17 03:55:07 PM
#243732   Something definitely needs to be lined up. PuraCap mrwrn2010 02/22/17 03:52:19 PM
#243731   k mrwrn2010 02/22/17 03:44:39 PM
#243730   Dilution stops in 5 weeks. (Although dilution aELmTPa 02/22/17 03:39:33 PM
#243728   It's pretty obvious a bigger deal is being aELmTPa 02/22/17 03:36:14 PM
#243727   The probability IMO is very high that it lasers 02/22/17 03:34:01 PM
#243726   A Lincoln type contract will no longer Jimmy Joe 02/22/17 03:31:49 PM
#243725   Elite needs its tape painted green today !!!!!!!!!!!!!!!! IB_ 02/22/17 03:30:24 PM
#243724   GREEN aELmTPa 02/22/17 03:29:38 PM
#243723   www.trade.education/wp-content/uploads/warren-buffett-quotes.png aELmTPa 02/22/17 03:24:42 PM
#243722   I think what Elite is saying is their namtae 02/22/17 03:23:26 PM
#243721   Generic Embeda filing tomorrow or next week??? aELmTPa 02/22/17 03:20:44 PM
#243720   She's bottomed out!!!! aELmTPa 02/22/17 03:18:21 PM
#243719   Correct.it actually is funny that the only clarity dr_lowenstein 02/22/17 03:16:02 PM
#243718   RSI is around 32/33 - plan accordingly! Couch 02/22/17 02:58:12 PM
#243717   Again, sorry, the PPS has not been that Couch 02/22/17 02:55:52 PM
#243716   After BE results and partnership announcement in 3 aELmTPa 02/22/17 02:48:50 PM
#243715   Ive increased my bid for Elite to .049. namtae 02/22/17 02:16:58 PM
#243713   Sorryt as I've stated, SEC filings prove me Couch 02/22/17 01:49:45 PM
#243712   Did news hit Business Wire about a REVERSE SPLIT?? namtae 02/22/17 01:46:56 PM
#243710   $ELTP's FDA officialy approved Pipeline as of DECEMBER lasers 02/22/17 01:41:10 PM
#243709   because we are savvy traders dr_lowenstein 02/22/17 01:37:01 PM
#243708   Sorry but the only thing we know as namtae 02/22/17 01:27:29 PM
#243707   I'm just wondering how all the traders always mrwrn2010 02/22/17 01:22:03 PM
#243706   Sorry ELTP's SEC filings clearly state Elite met Couch 02/22/17 01:14:49 PM
#243705   Might want to reread some of those posts Couch 02/22/17 01:07:32 PM
#243704   Start over LOL!! namtae 02/22/17 12:50:02 PM
#243703   yeah that was the good one, had three dr_lowenstein 02/22/17 12:43:48 PM
#243702   no actually I do not know that, and dr_lowenstein 02/22/17 12:42:01 PM
#243701   Sorry but theres nothing in that Elite PR namtae 02/22/17 12:37:35 PM
#243700   You know as well as I do that aELmTPa 02/22/17 12:35:17 PM
#243699   LOL that was THEN, this is NOW dr_lowenstein 02/22/17 12:18:35 PM
#243698   Thanks but I already have. It's in ELTP's Couch 02/22/17 11:52:20 AM
#243697   WOW, thats great and really believable!! namtae 02/22/17 11:47:10 AM
#243696   PuraCap agrees they paid $2.5 million in milestones NASDAQ2020 02/22/17 11:31:57 AM
#243695   Market makers trying hard to keep Elite from namtae 02/22/17 11:16:00 AM
#243694   Obviously Purecrap does not agree, hmmmmmm, wonder what dr_lowenstein 02/22/17 11:13:44 AM
#243693   @Couch: Some of your most recent posts Sixman 02/22/17 11:06:12 AM
#243692   The question is why would they not? NASDAQ2020 02/22/17 11:02:02 AM
#243691   Prove it!! namtae 02/22/17 11:01:42 AM
PostSubject